[{"id":"ce9dfb12-840f-46f6-b8d1-947639822665","acronym":"Morpheus Lung","url":"https://clinicaltrials.gov/study/NCT03337698","created_at":"2021-01-18T16:29:17.212Z","updated_at":"2025-02-25T13:48:26.615Z","phase":"Phase 1/2","brief_title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","source_id_and_acronym":"NCT03337698 - Morpheus Lung","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-20"},{"id":"9a2be334-2a03-47f4-bac6-d53ac52c474b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05286801","created_at":"2022-03-18T11:54:26.510Z","updated_at":"2025-02-25T14:08:43.679Z","phase":"Phase 1/2","brief_title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","source_id_and_acronym":"NCT05286801","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFA • SMARCB1","pipe":" | ","alterations":" SMARCA4 mutation","tags":["TNFA • SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-19"},{"id":"51e03560-3fbd-46cb-a1fe-077e9eea8d40","acronym":"","url":"https://clinicaltrials.gov/study/NCT05681039","created_at":"2023-01-11T14:59:21.452Z","updated_at":"2025-02-25T15:44:59.452Z","phase":"Phase 2","brief_title":"Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).","source_id_and_acronym":"NCT05681039","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • carboplatin • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/02/2023","start_date":" 06/02/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-02-10"},{"id":"d0347077-1070-49c3-a0e1-7799efd634bd","acronym":"SKYSCRAPER-05","url":"https://clinicaltrials.gov/study/NCT04832854","created_at":"2021-04-06T11:55:21.945Z","updated_at":"2025-02-25T15:19:05.163Z","phase":"Phase 2","brief_title":"A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04832854 - SKYSCRAPER-05","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • carboplatin • gemcitabine • paclitaxel • pemetrexed • tiragolumab (RG6058)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/23/2021","start_date":" 04/23/2021","primary_txt":" Primary completion: 03/05/2025","primary_completion_date":" 03/05/2025","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2025-02-10"},{"id":"f7fcbd54-143e-4657-9b77-27581b5037f3","acronym":"Morpheus-Liver","url":"https://clinicaltrials.gov/study/NCT04524871","created_at":"2021-01-18T21:40:19.145Z","updated_at":"2025-02-25T15:26:31.453Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","source_id_and_acronym":"NCT04524871 - Morpheus-Liver","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • IO-108 • SAR439459 • imdatifan (NKT2152) • muzastotug (ADG126) • tobemstomig (RG6139)"],"overall_status":"Recruiting","enrollment":" Enrollment 518","initiation":"Initiation: 11/01/2020","start_date":" 11/01/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-10"},{"id":"5741b2e4-403a-47d5-b489-ab51fac66036","acronym":"","url":"https://clinicaltrials.gov/study/NCT05645692","created_at":"2022-12-09T14:57:54.227Z","updated_at":"2025-02-25T16:39:31.560Z","phase":"Phase 2","brief_title":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","source_id_and_acronym":"NCT05645692","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 204","initiation":"Initiation: 04/13/2023","start_date":" 04/13/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-02-06"},{"id":"b5311e32-e5a1-4a67-a74a-af139d0dfb7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04958811","created_at":"2021-07-12T15:53:06.793Z","updated_at":"2025-02-25T16:38:29.835Z","phase":"Phase 2","brief_title":"Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC","source_id_and_acronym":"NCT04958811","lead_sponsor":"Georgetown University","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK wild-type • ROS1 wild-type","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK wild-type • ROS1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/21/2021","start_date":" 12/21/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-06"},{"id":"f3c62253-8046-49b1-bb25-cd529c350b91","acronym":"MORPHEUS-PDAC","url":"https://clinicaltrials.gov/study/NCT03193190","created_at":"2021-01-18T15:44:27.682Z","updated_at":"2025-02-25T16:36:54.744Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","source_id_and_acronym":"NCT03193190 - MORPHEUS-PDAC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • gemcitabine • 5-fluorouracil • Cotellic (cobimetinib) • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • Actemra IV (tocilizumab) • tiragolumab (RG6058) • etrumadenant (AB928) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide) • selicrelumab (RG7876) • simlukafusp alfa (RG7461)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 340","initiation":"Initiation: 07/05/2017","start_date":" 07/05/2017","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2025-02-06"},{"id":"b72eb8f1-94d0-4f21-ae23-71349994cf41","acronym":"AFT-57","url":"https://clinicaltrials.gov/study/NCT05798663","created_at":"2023-04-04T16:04:15.011Z","updated_at":"2025-02-25T17:02:30.093Z","phase":"Phase 2","brief_title":"Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC","source_id_and_acronym":"NCT05798663 - AFT-57","lead_sponsor":"Alliance Foundation Trials, LLC.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 12/07/2023","start_date":" 12/07/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-03"},{"id":"db660b09-0f52-4a82-9f38-79007e8d5211","acronym":"MORPHEUS mUC","url":"https://clinicaltrials.gov/study/NCT03869190","created_at":"2021-01-18T19:04:50.965Z","updated_at":"2025-02-25T13:18:52.965Z","phase":"Phase 1/2","brief_title":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","source_id_and_acronym":"NCT03869190 - MORPHEUS mUC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • gemcitabine • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (ONO-7913) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • RG7827 • lomvastomig (RG7769)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 06/01/2019","start_date":" 06/01/2019","primary_txt":" Primary completion: 10/03/2024","primary_completion_date":" 10/03/2024","study_txt":" Completion: 05/21/2026","study_completion_date":" 05/21/2026","last_update_posted":"2025-01-03"},{"id":"d5cf9deb-5221-48da-8860-edd0ad9556de","acronym":"IMperator","url":"https://clinicaltrials.gov/study/NCT06331598","created_at":"2025-02-26T08:19:48.665Z","updated_at":"2025-02-26T08:19:48.665Z","phase":"Phase 2","brief_title":"A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)","source_id_and_acronym":"NCT06331598 - IMperator","lead_sponsor":"Hoffmann-La Roche","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2024","start_date":" 11/30/2024","primary_txt":" Primary completion: 10/20/2028","primary_completion_date":" 10/20/2028","study_txt":" Completion: 09/20/2029","study_completion_date":" 09/20/2029","last_update_posted":"2024-12-24"},{"id":"ac47ac70-8d3e-44cd-9e5c-4352a399115f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05459129","created_at":"2022-07-14T13:54:32.957Z","updated_at":"2024-07-02T16:34:26.668Z","phase":"Phase 1/2","brief_title":"A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)","source_id_and_acronym":"NCT05459129","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • paclitaxel • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 04/13/2023","start_date":" 04/13/2023","primary_txt":" Primary completion: 08/11/2024","primary_completion_date":" 08/11/2024","study_txt":" Completion: 08/11/2024","study_completion_date":" 08/11/2024","last_update_posted":"2024-06-12"},{"id":"e2d54c14-c32b-40ed-857b-e3c6d02e177f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05715281","created_at":"2023-02-08T18:00:05.180Z","updated_at":"2024-07-02T16:34:36.920Z","phase":"Phase 2","brief_title":"Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial","source_id_and_acronym":"NCT05715281","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCA4 mutation","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/26/2023","start_date":" 09/26/2023","primary_txt":" Primary completion: 10/15/2026","primary_completion_date":" 10/15/2026","study_txt":" Completion: 10/15/2026","study_completion_date":" 10/15/2026","last_update_posted":"2024-06-10"},{"id":"753d5f8f-02a0-4ca0-9711-5eef163c02e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03784326","created_at":"2021-01-18T18:42:52.626Z","updated_at":"2024-07-02T16:34:58.959Z","phase":"Phase 2","brief_title":"Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma","source_id_and_acronym":"NCT03784326","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • tiragolumab (RG6058) • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-04"},{"id":"ee15de22-b96e-4782-9dfa-de6fb61fba65","acronym":"MoST-TAP","url":"https://clinicaltrials.gov/study/NCT06003621","created_at":"2023-08-22T15:08:28.367Z","updated_at":"2024-07-02T16:35:00.422Z","phase":"Phase 2","brief_title":"Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients","source_id_and_acronym":"NCT06003621 - MoST-TAP","lead_sponsor":"Omico","biomarkers":" PD-L1 • TMB • CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression • PD-L1 amplification","tags":["PD-L1 • TMB • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Pegasys (pegylated interferon α -2a) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 12/15/2023","start_date":" 12/15/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2024-05-29"},{"id":"2b19a779-eed1-4804-84fe-fd681112b627","acronym":"SKYSCRAPER-03","url":"https://clinicaltrials.gov/study/NCT04513925","created_at":"2021-01-18T21:38:00.569Z","updated_at":"2024-07-02T16:35:01.120Z","phase":"Phase 3","brief_title":"A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04513925 - SKYSCRAPER-03","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Imfinzi (durvalumab) • tiragolumab (RG6058)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 829","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2024-05-24"},{"id":"66295375-7bb9-499f-9a29-4931cfd6243c","acronym":"NeoACTIVATE","url":"https://clinicaltrials.gov/study/NCT03554083","created_at":"2021-01-18T17:29:17.667Z","updated_at":"2024-07-02T16:35:01.056Z","phase":"Phase 2","brief_title":"Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma","source_id_and_acronym":"NCT03554083 - NeoACTIVATE","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600 • BRAF wild-type","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/05/2018","start_date":" 10/05/2018","primary_txt":" Primary completion: 06/29/2025","primary_completion_date":" 06/29/2025","study_txt":" Completion: 06/29/2025","study_completion_date":" 06/29/2025","last_update_posted":"2024-05-24"},{"id":"a29c19e9-6ecb-46de-9fed-df8d47fbf354","acronym":"SKYSCRAPER-06","url":"https://clinicaltrials.gov/study/NCT04619797","created_at":"2021-01-19T20:34:15.566Z","updated_at":"2024-07-02T16:35:01.109Z","phase":"Phase 2/3","brief_title":"A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04619797 - SKYSCRAPER-06","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 542","initiation":"Initiation: 12/14/2020","start_date":" 12/14/2020","primary_txt":" Primary completion: 05/14/2027","primary_completion_date":" 05/14/2027","study_txt":" Completion: 05/14/2027","study_completion_date":" 05/14/2027","last_update_posted":"2024-05-24"},{"id":"5339312c-848e-4c0d-aed2-e48d851689d4","acronym":"MORPHEUS-EC","url":"https://clinicaltrials.gov/study/NCT03281369","created_at":"2021-01-18T16:12:10.112Z","updated_at":"2024-07-02T16:35:06.566Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)","source_id_and_acronym":"NCT03281369 - MORPHEUS-EC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1 • TIGIT","pipe":" | ","alterations":" HER-2 negative • HER-2 expression","tags":["HER-2 • PD-L1 • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium • tiragolumab (RG6058) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 410","initiation":"Initiation: 10/13/2017","start_date":" 10/13/2017","primary_txt":" Primary completion: 08/24/2024","primary_completion_date":" 08/24/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-05-01"},{"id":"715d1c6b-4590-4d65-b4fb-968075ff03b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05116202","created_at":"2023-07-21T01:09:41.714Z","updated_at":"2024-07-02T16:35:06.758Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)","source_id_and_acronym":"NCT05116202","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • tiragolumab (RG6058) • tobemstomig (RG6139)"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 02/02/2022","start_date":" 02/02/2022","primary_txt":" Primary completion: 09/22/2023","primary_completion_date":" 09/22/2023","study_txt":" Completion: 03/27/2024","study_completion_date":" 03/27/2024","last_update_posted":"2024-05-01"},{"id":"9d338c0a-6d59-429b-8a8a-37a50d61f225","acronym":"CITYSCAPE","url":"https://clinicaltrials.gov/study/NCT03563716","created_at":"2021-01-17T17:11:38.863Z","updated_at":"2024-07-02T16:35:06.975Z","phase":"Phase 2","brief_title":"A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03563716 - CITYSCAPE","lead_sponsor":"Genentech, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 08/10/2018","start_date":" 08/10/2018","primary_txt":" Primary completion: 06/30/2019","primary_completion_date":" 06/30/2019","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-04-30"},{"id":"3529b8e1-c332-4d7d-bd8e-ff3e7f5d654d","acronym":"SKYSCRAPER-09","url":"https://clinicaltrials.gov/study/NCT04665843","created_at":"2021-01-19T20:43:37.679Z","updated_at":"2024-07-02T16:35:09.237Z","phase":"Phase 2","brief_title":"A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck","source_id_and_acronym":"NCT04665843 - SKYSCRAPER-09","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 03/02/2021","start_date":" 03/02/2021","primary_txt":" Primary completion: 09/20/2023","primary_completion_date":" 09/20/2023","study_txt":" Completion: 10/02/2024","study_completion_date":" 10/02/2024","last_update_posted":"2024-04-17"},{"id":"7f5e0538-e916-4660-bced-86087916c70f","acronym":"SKYSCRAPER-01","url":"https://clinicaltrials.gov/study/NCT04294810","created_at":"2021-01-18T20:50:19.852Z","updated_at":"2024-07-02T16:35:09.924Z","phase":"Phase 3","brief_title":"A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04294810 - SKYSCRAPER-01","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 620","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 02/21/2025","primary_completion_date":" 02/21/2025","study_txt":" Completion: 02/21/2025","study_completion_date":" 02/21/2025","last_update_posted":"2024-04-12"},{"id":"5d4ead87-a481-45f7-abd4-aff0d2eb0762","acronym":"","url":"https://clinicaltrials.gov/study/NCT03977467","created_at":"2023-02-09T19:00:27.700Z","updated_at":"2024-07-02T16:35:11.256Z","phase":"Phase 2","brief_title":"Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor","source_id_and_acronym":"NCT03977467","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" PD-L1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/30/2019","start_date":" 08/30/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-05"}]